Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA: Purchasing Control Troubles Causing Recalls; Approved Supplier Lists Lack Details

This article was originally published in The Silver Sheet

Executive Summary

FDA’s inspectional approach might change in an effort to curb recalls related to purchasing controls, the agency says. “Do I believe we need to highlight supplier control and purchasing control under our current compliance program and current way of inspecting? Absolutely,” said CDRH’s Kim Trautman, who is heading up FDA’s review of its Quality System Inspection Technique (QSIT). Agency investigators are already being trained to delve deeper into supplier control issues when conducting facility inspections. FDA also says that firms are falling down when creating detailed approved supplier lists. Many companies are “adding only the name of a vendor to an approved supplier list. That practice needs to be adjusted,” Trautman said. Meanwhile, manufacturer Welch Allyn describes how it is using “lean” principles to clean up its approved supplier list, which includes about 2,500 vendors.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts